Abstract. In the present study, we investigated whether a novel benzopyranylindol analogue, KR-31466 (KR466) (1-[(2S,3R,4S)-3,4-dihydro-2-dimethoxymethyl-3-hydroxy-2-methyl-6-nitro-2H-1-benzopyran-4-yl]-1H-indole-2-carboxylic acid ethyl ester) can attenuate hypoxic injury in heart-derived H9c2 cells and, if so, whether the protective effect of KR466 is mediated through mitochondrial ATP-sensitive potassium (mtK ATP ) opening. The treatment of H9c2 cells with KR466 (3 -30 mM) significantly reduced hypoxia-induced cell death in a concentration-dependent manner, as shown by lactate dehydrogenase release and propidium iodide-uptake. In addition, KR466 (10 mM) significantly reduced the increase in hypoxia-induced TUNEL-positive cells, suggesting its anti-apoptotic potential in H9c2 cells. The protective effects of KR466 were abolished by 5-hydroxydecanoate, a specific blocker of the mtK ATP channel, suggesting the involvement of the mtK ATP channel in the protective effect of KR466. A specific inhibitor of protein kinase C (PKC), chelerythrine (3 m M), significantly attenuated the protective effect of KR466 against hypoxia-induced cardiac cell death. In conclusion, our results suggest that KR466 can protect H9c2 cells from hypoxia-induced death through mtK ATP channel opening and PKC activation.
Introduction
Ischemic preconditioning (IPC) is an endogenous protective mechanism in which brief episodes of ischemia and reperfusion paradoxically render the myocardium resistant to a subsequent, more sustained ischemic insult (1) . This phenomenon is currently the subject of intensive investigation, because it has been recognized as one of the most powerful means of attaining myocardial protection (2) . Although the precise signal transduction pathways involved in IPC are not fully elucidated, many candidate molecules such as adenosine, protein kinase C (PKC), and ATP-sensitive potassium (K ATP ) channel have been identified as essential elements for triggering and maintenance of protection (3) .
The PKC family of serine / threonine kinases has long been implicated as a mediator of IPC; activation of PKC correlates closely with the cardiac protection mediated by IPC in various animals (4), human (5) and cultured cardiomyocytes (6) . In addition, cardioprotection is induced by activators of PKC and abolished by inhibitors of PKC (7) .
Opening of K ATP channels has been regarded as a promising approach for mimicking IPC; thus, a substantial amount of effort has been focused on finding novel K ATP channel openers. Although we previously found that the new benzopyran derivative KR-30450 (SKP450) exerts cardioprotective effect via K ATP channels (8), we still need more cardioselective K ATP channel openers. In such attempts, a new benzopyranylindol analogue KR-31466 (KR466) was discovered as anti-ischemic agent, which has been previously demonstrated to have a protective effect against ischemic injury in the isolated rat heart model without vasorelaxant activity (9) . However, the cellular targets of KR466 responsible for the initiation of protection in the heart are not clear. Therefore, the present study was designed to determine whether KR466 can exert a protective effect against hypoxic injury in cultured cardiomyocytes and, if so, whether mitochondrial K ATP (mtK ATP ) channel and PKC is involved in the coupling mechanism by which KR466 produces cardioprotection, by using pharmacologic inhibitors.
Materials and Methods

Cell cultures and drug treatment
H9c2 cells derived from rat heart were obtained from American Type Culture Collection (Rockville, MD, USA). H9c2 cells were cultured in Dulbecco's modified Eagle's medium / medium 199 (4:1) (DMEM) containing 5.5 mM glucose supplemented with 10% fetal bovine serum before experiment. Cells were treated with KR466 (3, 10, or 30 m M) or diazoxide (DZX, 100 mM), a known mtK ATP activator, 1 h before and during hypoxia. A specific inhibitor of mtK ATP (10), 5-hydroxydecanoate (5HD was added with KR466 or DZX. The concentrations and durations of drug-treatment were chosen on the basis of preliminary studies (data not shown).
Hypoxic condition
For hypoxic challenge, H9c2 cells were transferred into anaerobic chamber (Forma Scientific, Marietta, OH, USA) maintained at 37°C with a humidified atmosphere of 5% CO 2 and 10% H 2 and 85% N 2 as described before (11) . In the chamber, culture medium was replaced with serum-free, glucose-free DMEM saturated with N 2 for 1 h before use. Normoxic incubation of myocytes in serum-free DMEM was conducted in a water-jacketed incubator gassed with 95% air and 5% CO 2 at 37°C.
Lactate dehydrogenase (LDH) assay
To measure overall cell injury, the activity of LDH released into the medium 10 h after hypoxic insult was assayed as described previously (11) . Aliquots from culture media samples (released LDH) were assayed by spectrophotometric analysis at 340 nm. The percent LDH was calculated from the maximum LDH release (100%) induced by lysing cells with 0.1% Triton X-100.
Propidium iodide (PI) staining
To examine the extent of cell death, we stained the cells with PI (10 mg/ ml), which is normally taken up by dead cells, but not by living cells (11), 8 h after hypoxic insult. The percent cell death was calculated from the number of PI-stained cells divided by total cell count.
In situ terminal deoxynucleotidyl transferase UTP nick end labeling (TUNEL) assay
In situ labeling of fragmented DNA was performed by TUNEL assay with the commercially available ApopTag Plus kit (Oncor, Gaithersburg, MD, USA). Monolayers of H9c2 cells were grown on 24-well plates and fixed with 4% paraformaldehyde. Then nucleosome-sized DNA fragments were tailed with digoxigenin nucleotide and reacted with fluorescein-conjugated antidigoxigenin antibodies. The nucleus was counterstained with hematoxyline.
1H-indole-2-carboxylic acid ethyl ester, was synthesized by Korea Research Institute of Chemical Technology, Daejon, Korea. KR466 and DZX (Sigma-Aldrich, Seoul, Korea) were dissolved in dimethyl sulfoxide (DMSO) as 100 mM stock solutions. The final concentration of DMSO was 0.1% and this concentration was found to have no effect on H9c2 cell viability. 5HD purchased from Sigma-Aldrich, was dissolved in distilled water and diluted with media to give a final concentration of 100 m M.
Statistical analyses
All data were expressed as the mean ± S.E.M. Numerical data were compared using Student's t-test for paired observations between two groups. A P value of <0.05 was considered significant.
Results
The structure of KR466 was shown in Fig. 1 . Figure 2A shows the preventive effect of KR466 from 10 h-hypoxia induced LDH release in H9c2 cells, and the KR466-induced protective effect was revealed maximally after 10 h-hypoxia compared to those for 6 hor 8 h-hypoxia (data not shown). In H9c2 cells exposed to hypoxia for 10 h, LDH release was remarkably increased up to 67.3 ± 3.4% compared to that in the normoxic condition (10.2 ± 2.9%). This increase in LDH release was inhibited by treatment with KR466 (3 -30 m M) in a concentration-dependent manner ( Fig. 2A) . Figure 2B shows the effect of KR466 on hypoxia-induced cell death, which was evaluated by PI uptake, another well-known indicator of cell viability. Since considerable amount of cells began to be detached from culture plate after 9-h hypoxia, we performed PIstaining and also TUNEL assay just after 8-h hypoxia rather than 10-h hypoxia. While 30.2 ± 3.0% of cells were stained with PI 8 h after hypoxia, the treatment of cells with 10 and 30 m M of KR466 markedly decreased the uptake of PI (7.9 ± 2.4 and 3.5 ± 2.5, respectively) (Fig. 2B) .
To investigate whether the protective effect of KR466 was mediated through mtK ATP channels, we used a specific inhibitor of mtK ATP channels, 5HD. Figure 3 shows the effect of 5HD on KR466 and DZX-induced protection against hypoxia-induced cell death. The co-treatment of cells with 10 mM KR466 and 100 mM 5HD markedly increased hypoxia-induced PI uptake (27.4 ± 2.9%) compared to that in cells treated with 10 m M KR466 alone (8.1 ± 1.3%). 5HD also reversed the protective effect of DZX (7.8 ± 2.5%) on hypoxiainduced PI uptake by increasing up to 24.3 ± 3.1%.
TUNEL-staining was performed for evaluation of anti-apoptotic activity of KR466. As shown in Fig. 4 , the amount of TUNEL-positive cells were 20.9 ± 2.4% in vehicle-treated cells exposed to hypoxia for 8 h, and this amount was decreased by the treatment with 10 mM KR466 (4.28 ± 1.2%). KR466-induced decrease in the number of TUNEL-positive cells 8 h after hypoxia was significantly increased by simultaneous treatment of cells with 5HD (17.1 ± 2.0%).
In Fig. 5 , the effect of chelerythrine (Chel, 3 m M) on KR466-induced protection is shown. PI uptake in KR466-treated cells (7.81 ± 0.8%) was significantly increased by co-treatment with Chel (24.4 ± 3.2%).
Discussion
In the present study, we demonstrated that the benzopyranylindol analogue KR466 can exert a protective effect against hypoxia-induced cell death, at least in part, through mtK ATP and PKC.
The results from our study showed that the treatment with KR466 protected H9c2 cells against hypoxiainduced death, in a concentration-dependent manner, as shown by LDH release and PI-staining after hypoxic insult (serum-, glucose-, and oxygen-free). In addition, KR466 (10 m M) significantly reduced the increase in the number of TUNEL-positive cells induced by hypoxia, suggesting its anti-apoptotic potential in H9c2 cells.
Although the molecular basis of IPC remains elusive, a number of studies including our previous report (8, 12, 13) have demonstrated that the K ATP channel is an important component in the mechanism of IPC. While early studies suggested that the cardioprotective effects of K ATP channel openers were mediated through the sarcolemmal K ATP (sarcK ATP ) channel (14) , a substantial body of recent evidence implicates that mtK ATP channel opening plays a central role in the acquisition of the protection by IPC (15, 16) . The involvement of mtK ATP channel in the mechanism of cardioprotection has been supported by the results that IPC-mediated cardioprotection was abolished by 5HD, a selective mtK ATP channel blocker, in various animals and human heart (17 -19) . A selective mtK ATP channel activator DZX has been recognized to exert cardioprotective effect against ischemia-reperfusion injury in rat and human heart (19, 20) . In addition, several benzopyran K ATP openers have been shown to open mtK ATP channels within their cardioprotective concentration range, suggesting the mtK ATP channel as the site of cardioprotective action (21) . Based on these considerations, we examined whether the mechanism of the cardioprotection by KR466 involves the mtK ATP channel, by using 5HD in our cardiomyocyte model of hypoxia (22) . Consistent with other studies, we confirmed the ability of 5HD to inhibit DZX-induced cardioprotection in H9c2 cells. The protective effect conferred by KR466 (10 mM) was almost completely blocked by cotreatment of H9c2 cells with 5HD, suggesting that the mtK ATP channel is an important component of the coupling mechanism by which KR466 produces cardioprotection. PKC has long been considered as an essential element in the signal pathways of cardioprotection by IPC (4). We previously reported the role of PKC as a mediator of cardioprotection in H9c2 cells (11) and isolated rat heart model (23) . Recently, it has been suggested that the protective effect of mtK ATP channel opener is associated with PKC (24) , by showing that the protective effect of DZX was not observed in hearts after PKC downregulation (24) . Thus, in this study, we wanted to determine whether PKC is involved in the KR466-induced cardioprotective mechanism, by using a pharmacological inhibitor. Our result showed that the specific PKC inhibitor chelerythrine (3 m M) significantly blocked the protective effect of KR466 against hypoxiainduced H9c2 cell death. This result suggests that the activation of PKC may be, at least in part, involved in KR466-induced cardioprotection, although it remains to be investigated whether KR466 directly increases PKC activity. This result further supports other studies showinhg that the effects of both PKC and mtK ATP channel are interlinked (25) . The link between PKC activation and mtK ATP channel opening has been provided by evidence that the PKC activator, phorbol 12-myristate 13-acetate (PMA) potentiated and accelerated the effect of DZX and that this effect of PMA was blocked by 5HD (13) . A recent report suggests that the mtK ATP channel is the ultimate target for protection against ischemic injury by showing that diazoxide activates nuclear factor kB (NFkB) via PKC activation, resulting up-regulation of inducible nitric oxide synthase and that nitric oxide triggers the opening of mtK ATP channel as an end effector of cardioprotection during late PC (26) . This concept is consistent with the finding that activation of the mtK ATP channel restores mitochondrial membrane potential, inhibits cytochrome c release, inhibits apoptosis, reduces calcium overload, and augments ATP synthesis in the mitochondria.
There are multiple isozymes of PKC, and at least six different PKC isozymes have been identified in rat cardiac myocytes (27) , where individual isozymes translocate to characteristic intracellular sites following activation with each isozyme playing a different role in myocytes. In the immunocytochemical study, PKC-d has been translocated to the mitochondria and sarcolemma after treatment with DZX, producing cardiac protection against ischemia (28) . Furthermore, in PKC-d downregulated hearts, cardioprotection by DZX was abolished (24) . In spite of these reports about the role of PKC-d (29) as a mediator of mtK ATP channel opening, it is still unclear which isozymes of PKC are coupled to protective mechanism by mtK ATP channel opening. Thus, further study is needed to determine which isotype of PKC is linked to KR466-induced cardioprotection. 
